Abstract: Liquid hydrocarbons are gelled by the introduction of a phosphate ester and a crosslinking agent. Gelling times and viscosities are improved through the use of an enhancer which is, preferably, an oxyalkylated amine or a blend of an oxyalkylated amine with another amine or a non-nitrogen-containing component. Preferred phosphate esters are ether phosphate esters.

Abstract: The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (burns), surgical trauma, accidental trauma, hemorrhagic shock and the like. The invention is also related to methods for preventing or reducing bacterial translocation, adult respiratory distress syndrome, adherence of blood cells and platelets to endothelial cells and pulmonary hypertension. In accordance with the present invention, these conditions are prevented or reduced by administering a dehydroepiandrosterone (DHEA) derivative as defined herein.

Abstract: Described are 14,17-C.sub.2 -bridged steroids of the formula (I) defined in the specification. The compounds are available, even after peroral administration, with high gestagenic action and are suitable for the production of pharmaceutical agents.

Abstract: The invention relates to a process for catalytic hydrogenation of non-hormonal unsaturated plant steroids and unsaturated plant-based fatty acids and triglycerides thereof using a metal catalyst bound to a polymer support containing grafted groups. The invention also relates to regeneration of a used catalyst.

Abstract: Disclosed are compounds of formula (A) ##STR1## wherein X, R.sub.1 and Y are as defined by the specification. The compounds are useful as antiandrogenic agents.

Abstract: Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.

Abstract: The present invention is directed to compounds of formula I ##STR1## wherein the substituents are as defined in the specification. Also disclosed are compositions and method of use of the compounds.

Abstract: 1.alpha.,24(S)-Dihydroxy vitamin D.sub.2 which is useful as an active compound of pharmaceutical compositions for the treatment of disorders of calcium metabolism and for various skin disorders. The invention also includes preparation of synthetic 1.alpha.,24(S)-dihydroxy vitamin D.sub.2 starting from ergosterol which is converted in six steps to 24-hydroxyergosterol. 24-Hydroxyergosterol is irradiated and thermally converted to 24-hydroxy vitamin D.sub.2 which is converted in six steps to 1.alpha.,24(S)-dihydroxy vitamin D.sub.2. The syntheses also produced novel intermediates.

Abstract: Bisphosphonate derivatives of hydroxy steroids which are bone resorption inhibitors or bone formation stimulators, the derivatives having at least one group A in place of a hydroxy group on the steroid molelcule, where A is a group of forumla (A) where X is: (i) St--O--CO-- where St is the residue of the hydroxy steroid given by removal of an OH group; or (ii) R.sup.1 --O--CO-- where R.sup.1 is an alkyl, alkenyl, cycloalkyl, aralkyl or aryl group, any of which may optionally be substituted, and the salts and solvates of these compounds. The steroid is typically 17.beta.-oestradiol, oestrone, testosterone, norethindrone, androsterone, norethandrolone or nandrolone. The derivatives can be used in the treatment of bone disorders such as osteoporosis.

Abstract: Compounds represented by the following structural formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification. The compounds are disclosed as useful in the treatment of various forms of cancer.

Abstract: This invention describes the new 17-difluoromethylene-estratrienes of general formula I ##STR1## in which R.sup.1 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group,R.sup.5 is a methyl or ethyl group, andR.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group in .alpha.- or .beta.-position,R.sup.3 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyloxy group in .alpha.- or .beta.-position,R.sup.4 is a hydrogen atom in .alpha.- or .beta.-position, and A, B, D, E and G each is a hydrogen atom, and optionally at least one of substituent pairsG and R.sup.2, R.sup.2 and R.sup.4, R.sup.4 and A, A and R.sup.3, B and D, D and E is a double bond.

Abstract: The invention relates to a composition, in particular a cosmetic or dermatological composition, having an aqueous dispersion of vesicles with a lipid membrane, characterized in that the lipid membrane contains at least one carbamate of following formula (I): ##STR1## wherein R.sub.1 and R.sub.2 are defined in the specification.

Abstract: The invention relates to the novel compound mometasone furoate monohydrate, process for its preparation and pharmaceutical compositions containing said compound.

Abstract: 1.alpha.-hydroxy-vitamin D derivatives represented by formula ##STR1## wherein R.sub.1 represents a hydrogen atom or a hydroxyl group; and R.sub.2 represents a straight-chain or branched C.sub.2 -C.sub.7 alkyl, C.sub.2 -C.sub.7 alkenyl, or C.sub.2 -C.sub.7 alkynyl group. The compounds exhibit calcium metabolism regulating activity and differentiation stimulating activity on tumor cells, and are useful as treating agents for diseases caused by abnormal calcium metabolism, such as osteoporosis and osteomalacia, or as antitumor agents.

Abstract: Novel analogs of 1.alpha.,25-dihydroxyvitamin D.sub.3 which are selective agonists for the genomic responses or agonists or antagonists for the rapid cellular responses in a wide array of diseases in which 1.alpha.,25-dihydroxyvitamin D.sub.3 or its prodrugs are involved. Novel analogs have general formulae represented by compounds of groups I-V. A method for treatment and prevention of diseases connected with the endocrine system.

Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R31, R4, R5, R51 and R6 are as defined in the specification. The compounds are phosphodiesterase inhibitors. Also disclosed are pharmaceutical compositions and methods of use of the compounds.

Abstract: A new process for the preparation of 16.beta.-methyl-steroids of the formula ##STR1## and novel intermediates.

Abstract: The present invention relates to polyamine derivatives of the formula RHN-(CH.sub.2).sub.m -NH-(CH.sub.2).sub.n -NHR wherein m is an integer from 2 to 4, n is an integer from 3 to 10 and R is C.sub.2 -C.sub.6 alkyl or --(CH.sub.2).sub.p -Ar wherein Ar is phenyl or naphthyl and p is an integer from 0 to 2; and the pharmaceutically acceptable addition salts thereof which are useful as radioprotective agents. It relates also to the use of polyamines of the formula RHN-(CH.sub.2).sub.m -NH-(CH.sub.2).sub.n -NH-(CH.sub.2).sub.m -NHR wherein m is an integer from 2 to 4, n is an integer from 3 to 10 and R is C.sub.2 -C.sub.6 alkyl or --(CH.sub.2).sub.p -Ar wherein Ar is phenyl or naphthyl and p is an integer from 0 to 2; and the pharmaceutically acceptable addition salts thereof as radioprotective agents.

Abstract: A method for treatment of diseases caused by deficiency or overproduction of the vitamin D.sub.3 metabolites by administering analogs of 1.alpha.,25-dihydroxyvitamin D.sub.3. These analogs are selective agonists or antagonists for the genomic and rapid nongenomic cellular responses. A pharmaceutical composition comprising 1.alpha.,25-dihydroxyvitamin D.sub.3 analog.

Abstract: Steroid esters of formula I ##STR1## are described, wherein m, n and x are as defined by the specification. The compounds are distinguished from the basic hydroxy compounds by considerably improved solubility as well by increased biological activity and selectivity.The compounds are suitable for the production of pharmaceutical agents.